特刊推荐

临床药理学与治疗学的创新

Innovations in Clinical Pharmacology and Therapeutics

本期客座编辑：

Piet Hein van der Graaf

Leiden University

访问网址，查阅特刊推荐文章：

What is History? An Echo of the Past in the Future; A Reflex From the Future on the Past

何为历史？来自未来的过去回响；映照过去的未来返思

https://doi.org/10.1002/cpt.70089

Innovations in Clinical Pharmacology: Shaping the Future of Evidence Generation in Research, Development, and Utilization of Medicines

临床药理学创新：引领药物研发与应用中的证据生成迈向未来

https://doi.org/10.1002/cpt.70109

Seasons of Growth: Reflections on the CPT Editor-in-Training Program

成长之季：CPT培训主编项目心得感悟

https://doi.org/10.1002/cpt.70102

Expediting Drug Development in Japan: A PMDA Perspective

加速日本药物研发：基于PMDA视角的探讨

https://doi.org/10.1002/cpt.70022

Emerging Tools and Technologies for Microbiome-Aware Drug Development

微生物组导向药物研发的新兴工具与技术

https://doi.org/10.1002/cpt.70026

New Approach Methodologies: What Clinical Pharmacologists Should Prepare For

新方法学：临床药理学家的未来应对之策

https://doi.org/10.1002/cpt.70046

Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies

定量蛋白质组学在新方法学验证中的应用前景

https://doi.org/10.1002/cpt.70049

Innovations and Best Practices for Therapeutic Development in Pediatric Rare Diseases: A Model-Informed Drug Development Perspective

儿科罕见病治疗研发的创新与最佳实践：基于模型引导药物研发的视角

https://doi.org/10.1002/cpt.3683

Transforming Pharmacovigilance With Pharmacogenomics: Toward Personalized Risk Management

利用药物基因组学革新药物警戒：迈向个性化风险管理

https://doi.org/10.1002/cpt.70095

Clinical and Quantitative Pharmacology Considerations of mRNA Therapeutics and Vaccine Development: Bridging Translational and Platform Gaps for Enhanced Decision Making

基于临床与定量药理学的mRNA疗法及疫苗开发考量：弥合转化研究与平台技术鸿沟，助力决策优化

https://doi.org/10.1002/cpt.70085

History and Evolution of Innovations in Clinical Pharmacology

临床药理学的创新历程与演进轨迹

https://doi.org/10.1002/cpt.70048

Model-Informed Drug Development Applications and Opportunities in mRNA-LNP Therapeutics

基于模型引导的药物开发在mRNA-LNP疗法中的应用与机遇

https://doi.org/10.1002/cpt.3641

Primary care barriers and facilitators to nonpharmacologic treatments for low back pain: A qualitative pilot study

HIV药理数据资源库：为临床与临床前药代动力学研究建立信息共享新标准

https://doi.org/10.1002/cpt.3699

Clinical Trials With Pragmatic Elements: A Review of Use Cases and Real-World Data Utilization

含实用性要素的临床试验：应用场景与真实世界数据利用综述

https://doi.org/10.1002/cpt.70033

Pharmacomicrobiomics

药物微生物组学

https://doi.org/10.1002/cpt.70066

Quantitative Approaches to Accelerate MASH Drug Discovery and Development

量化策略加速MASH药物研发进程

https://doi.org/10.1002/cpt.70103

A Fast Path from Innovation to Safe and Effective Medicines

从创新到安全有效药物的快速通道

https://doi.org/10.1002/cpt.70107

Evolving Real-World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan—An Analysis of the 6-Year Trend

日本新药与再生医疗产品审评中真实世界数据与证据的应用演进——基于六年趋势分析

https://doi.org/10.1002/cpt.70081

High Virologic Suppression and Favorable Profiles of Two-Drug Antiretroviral Regimens in Africa: A Systematic Review of Current Evidence

非洲地区双药抗逆转录病毒疗法的高病毒抑制率与优良特性：当前证据的系统性综述

https://doi.org/10.1002/cpt.70106

Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy

临床药物遗传学实施联盟指南：NAT2基因型与肼屈嗪治疗

https://doi.org/10.1002/cpt.70071

Spatiotemporal Characterization of Sulfasalazine and 5-ASA Pharmacokinetics Using a Noninvasive Intestinal Sampling Device

基于无创肠道采样装置的柳氮磺胺吡啶与5-ASA药代动力学时空特征研究

https://doi.org/10.1002/cpt.70035

Supplementing Single-Arm Trials with External Control Arms—Evaluation of German Real-World Data

单臂试验结合外部对照组研究——德国真实世界数据评估

https://doi.org/10.1002/cpt.3684

Population Pharmacokinetics of siRNA JNJ-73763989 in Healthy Participants and Patients With Chronic Hepatitis B

JNJ-73763989 siRNA在健康受试者与慢性乙肝患者中的群体药代动力学研究

https://doi.org/10.1002/cpt.3690

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi-Omics and Multi-Modal Data Analysis

基于多组学与多模态数据分析的阿替洛尔治疗骨质疏松的再利用研究

https://doi.org/10.1002/cpt.3738

Microbiome-Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement

微生物组指导的剂量优化：探索肠道菌群对霉酚酸肠肝循环与治疗目标达成的影响

https://doi.org/10.1002/cpt.3740

A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure–Response Relationship during Treatment of Obesity with Tirzepatide

一种用于定量测定体成分改善及表征替西帕肽治疗肥胖期间暴露-反应关系的药理学方法

https://doi.org/10.1002/cpt.3750

Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter-Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinal™)

利用人类原代肠道三维模型（EpiIntestinal™）推进口服药物吸收、CYP3A4诱导及转运体介导相互作用的预测研究

https://doi.org/10.1002/cpt.70000

Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium (CPIC)

通过临床药物遗传学实施联盟（CPIC）推动全球临床药物基因组学发展

https://doi.org/10.1002/cpt.70005

A Hybrid Design Incorporating External Data to Evaluate Dexamethasone Intracameral Drug Delivery Suspension for Post-Cataract Surgery Inflammation

结合外部数据评估地塞米松前房内给药混悬液治疗白内障术后炎症的混合设计研究

https://doi.org/10.1002/cpt.70010

Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3-O-Sulfate (GCDCA-S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters

甘氨鹅脱氧胆酸3-O-硫酸酯（GCDCA-S）作为OATP1B3与OAT3转运体内源性生物标志物的群体药动学模型研究

https://doi.org/10.1002/cpt.70023

Cell and Gene Therapy Product Approvals in China: Insights into Clinical Trials and Regulatory Advances

中国细胞与基因治疗产品获批分析：临床试验进展与监管创新洞察

https://doi.org/10.1002/cpt.70099

Unlocking Potential of Generative Large Language Models for Adverse Drug Reaction Relation Prediction in Discharge Summaries: Analysis and Strategy

释放生成式大语言模型在出院小结中预测药物不良反应关系的潜力：分析与策略

https://doi.org/10.1002/cpt.70100

Corrigendum to “Model-Informed Once-Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis”

《基于模型信息的儿童、青少年及成人结核病患者贝达喹啉与德拉马尼每日一次给药策略》更正声明

https://doi.org/10.1002/cpt.70111

Erratum to “Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX-FP Prophylaxis in Hemophilia B: A Repeated Time-to-Event Analysis”

《rIX-FP预防治疗血友病B的剂量、凝血因子IX活性水平与出血风险关系研究：重复时间-事件分析》勘误表

https://doi.org/10.1002/cpt.70110

期刊简介

Clinical Pharmacology & Therapeutics（CPT）作为美国临床药理学与治疗学会（ASCPT）的旗舰期刊，是实验医学与临床医学领域权威的跨学科期刊，致力于发表治疗学的本质、作用机制、疗效及评价方面的前沿进展。

Citation Impact